

1 Article

# 2 Performance of FRAX in predicting fracture in the US 3 postmenopausal women with varied race and genetic 4 profiles

5 Qing Wu, MD, ScD<sup>1,2,\*</sup>, Xiangxue Xiao, MSPH<sup>1,2</sup> and Yingke Xu, MSPH<sup>1,2</sup>

6 <sup>1</sup> Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, NV 89154, USA;

7 <sup>2</sup> Department of Environmental and Occupational Health, School of Public Health, University of Nevada  
8 Las Vegas, NV 89154, USA;

9 \* Correspondence: [qing.wu@unlv.edu](mailto:qing.wu@unlv.edu); Tel.: +01-702-895-1439

10 Received: date; Accepted: date; Published: date

11 **Abstract:** Background: Whether the Fracture Risk Assessment Tool (FRAX) performed differently  
12 in estimating the 10-year fracture probability in women of different genetic profiling and race  
13 remained unclear. Methods: The genomic data in the Women's Health Initiative study was analyzed  
14 (n=23,981). the genetic risk score (GRS) was calculated from 14 fracture-associated single nucleotide  
15 polymorphisms (SNPs) for each participant. FRAX without bone mineral density (BMD) was used  
16 to estimate fracture probability. Results: FRAX significantly overestimated the risk of major  
17 osteoporotic fracture (MOF) in the WHI study. The most enormous overestimation was observed in  
18 women with low GRS (predicted/observed ratio [POR]: 1.61, 95% CI: 1.45-1.79), in Asian women  
19 (POR: 3.5, 95% CI 2.48-4.81), and in African American women (POR: 2.59, 95% CI: 2.33-2.87).  
20 Compared to the low GRS group, the 10-year probability of MOF adjusted for the FRAX score was  
21 21% and 30% higher in median GRS group and high GRS group, respectively. Asian, African  
22 American, and Hispanic women respectively had a 78%, 76%, and 56% lower hazard than Caucasian  
23 women after the FRAX score was adjusted for. The results were similar when for hip fractures.  
24 Conclusions: Our study suggested the FRAX performance varies significantly by both genetic  
25 profiling and race in postmenopausal women.

26 **Keywords:** genetic risk score (GRS); bone mineral density (BMD); single nucleotide polymorphism  
27 (SNP); Fracture risk assessment tool (FRAX).

28

## 29 1. Introduction

30 Osteoporotic fracture continues to be a critical public health problem worldwide [1, 2]. One  
31 main reason is that the incidence of osteoporotic fracture increases exponentially throughout one's  
32 life [3]. Approximately 40% of postmenopausal women will suffer at least one fracture in their  
33 lifetime [4-6]. Additionally, bone fractures often lead to devastating consequences, including  
34 functional decline, prolonged disability, and death [7]. With longevity increasing globally, the  
35 potentially high cumulative rate of osteoporosis and fractures, and the associated excess disability  
36 and mortality will lead to an inevitable increase in social and economic burdens worldwide [8, 9].

37 Furthermore, osteoporosis is a silent disease because bone loss occurs without any signs or  
38 symptoms [3]. Patients often do not aware that they have osteoporosis until a fracture occurs; thus,  
39 fracture prediction becomes critically important. Bone mineral density (BMD) can be used to  
40 stratify patients for fracture risk; however, it has low sensitivity [10]. Studies have found that most  
41 fractures occur in individuals who have a BMD above the threshold for osteoporosis [11, 12].  
42 Because many factors other than BMD, such as age, gender, weight, height, smoking, alcohol

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

43 consumption, medication, also contribute fracture risk, several algorithms have been developed to  
44 integrate these risk factors to assess fracture risk [16-20] more accurately. The Fracture Risk  
45 Assessment Tool (FRAX), which is the most widely used tool for fracture risk assessment, was  
46 developed by the Collaborating Centre for Metabolic Bone Diseases (Sheffield, UK). The FRAX is a  
47 computer-based program that computes the 10-year probability of major osteoporotic fracture  
48 (MOF, a composite of hip, humerus, forearm, and clinical vertebral fractures) and the hip fracture.  
49 The FRAX can be used with or without femoral neck BMD measurement [13]. Although FRAX  
50 improves fracture prediction over the BMD T-score method alone [14], the FRAX performance of  
51 predicting fracture risk varies in different study populations [15-17]. Hence, there is room for  
52 further improvement in fracture prediction.

53 FRAX was derived from nine cohorts and has been validated in 11 independent cohorts from  
54 around the world [14]. The US FRAX was calibrated from the data of the Rochester Epidemiology  
55 Project [18] cohort, which was composed predominantly of Caucasians [19]. For the US minorities,  
56 the FRAX estimates were adjusted basing on race-specific hip fracture incidence rates and race-  
57 specific mortality [20]. This adjustment was not empirically based. Racial/ethnic differences that  
58 influence fracture risk may not be adequately taken into account by US FRAX [21]. Additional  
59 studies are needed to examine the performance of FRAX in U. S. minorities.

60 Additionally, genetic profiling is an essential predisposition to bone deterioration and fragility  
61 fractures [22]. Genetic factors are also determinants of bone structure [23]. Although FRAX does not  
62 factor in genetic elements, mounting evidence shows that fracture susceptibility is genetically  
63 determined [24]. Virtually 50% of the variance in liability to fragility fracture is attributable to  
64 genetic elements [25]. With the advancement of genomic technologies in the past two decades,  
65 major genome-wide association studies (GWASs) and genome-wide meta-analyses have  
66 successfully identified numerous genetic loci associated with fracture [18, 26, 27]. To date, the  
67 largest genome-wide meta-analysis on fracture, which involved 32,961 participants, revealed 14  
68 single nucleotide polymorphisms (SNPs) associated with fracture [18]. However, it remains unclear  
69 how these SNPs cause bone fragility and associated fracture. As the allelic frequency of these  
70 discovered SNPs featured high variability in the population, and each SNP is associated with small  
71 effect size, the contribution of any single SNP to fracture susceptibility is expected to be minimal  
72 [28]. The cumulative effects of many associated genetic variants possibly cause osteoporotic fracture  
73 [29, 30]. Thus polygenic scores summarized from risk alleles at each locus have commonly been  
74 employed to quantify the overall genetic effect contributing to fracture risk [31].

75 The performance of FRAX with different genetic profiling has not been reported in the  
76 literature. The performance of FRAX in minorities of the US was rarely studied. Thus our study  
77 aimed 1) to evaluate whether FRAX performs differently in estimating the 10-year absolute  
78 probability of MOF and hip fracture in postmenopausal women with different polygenic risk  
79 scores, and 2) assess FRAX performance in the prediction of MOF hip fracture in minority women.  
80 We also examined if the interaction of race and polygene score impacts the performance of FRAX in  
81 fracture prediction.

## 82 **2. Experimental Section**

### 83 *2.1. Data Source*

84 The WHI study is a nationwide, long-term health study that has focused on heart disease, breast  
85 and colorectal cancer, and fragility fractures in postmenopausal women. Between 1993 and 1998, the  
86 WHI has enrolled 161,808 women aged 50 to 79 years into one or more randomized Clinical Trials or  
87 to an Observational Study (OS), which were conducted at 40 clinical centers nationwide. Participants  
88 were provided by mail or telephone with questionnaires annually in the observational study, or  
89 semiannually in the clinical trials. The Institutional Review Board at each participating institution  
90 approved study protocols and consent forms [32].

## 91 2.2. Participants

92 The female participants included in the present study were combined from four WHI sub-  
93 studies: WHI Genomics and Randomized Trials Network (GARNET); National Heart Lung and  
94 Blood Institute (NHLBI); Population Architecture using Genomics and Epidemiology (PAGE); and  
95 Women's Health Initiative Memory Study (WHIMS). These data were acquired through the database  
96 of Genotype and Phenotype (dbGap) ([https://www.ncbi.nlm.nih.gov/projects/gap/cgi-  
97 bin/study.cgi?study\\_id=phs000200.v12.p3](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3)) with the approval of the institutional review board at the  
98 University of Nevada, Las Vegas. The included participants were genotyped using either the Illumina  
99 (Illumina, San Diego, California) or Affymetrix 6.0 Array Set Platform (Affymetrix, Santa Clara,  
100 California). Participants who reported taking any medication known to influence osteoporosis,  
101 including bisphosphonates, calcitonin, parathyroid hormone, selective estrogen receptor modulators,  
102 luteinizing hormone-releasing hormone agents, and somatostatin agents, and participants who had  
103 incomplete information regarding risk factors included in FRAX, were excluded from the study  
104 sample. In total, 1,513 subjects were excluded from the present study, and there were 23,981 eligible  
105 participants from multiple racial backgrounds, genotype data, and adjudicated fracture outcomes  
106 available.

## 107 2.3. Outcomes: Incident Fractures

108 The primary outcomes are major MOF and hip fractures. The WHI participants were followed  
109 for 9 years on average from the baseline examination. The follow-up period was calculated from the  
110 enrollment (OS) or randomization (CT) to the time of the first fracture or death. People who did not  
111 experience a fracture or death were followed until the end of the initial WHI study. Self-reported  
112 fracture outcomes were identified by questionnaires semiannually for CT participants and annually  
113 for OS participants. Radiology reports were used to adjudicate all fractures in the CT, and hip  
114 fractures in the OS. Hip fractures were centrally or locally adjudicated using the same criteria. The  
115 agreement between central and local adjudication for hip fracture was 96%. Other types of fractures  
116 were locally adjudicated at clinical centers where BMD was not measured [32].

## 117 2.4. Genotyping

118 Genotype data produced from blood samples were acquired through dbGap. Genotype  
119 imputation was completed at the Sanger Imputation Server. The Haplotype Reference Consortium  
120 (HRC) reference panel and Positional Burrows-Wheeler Transform (PBWT) imputation algorithm  
121 were used for genotype imputation. All 14 fracture-associated SNPs, as reported by Estrada et al.  
122 [18], were successfully imputed.

## 123 2.5. Genetic risk scores

124 Genetic risk for fracture was quantified using a standardized metric described by Estrada et al.  
125 [18]. Briefly, this metric allows the composite assessment of genetic risk in complex traits by  
126 summarizing the genetic predisposition. Based on 14 fracture-associated SNPs discovered in the  
127 largest genome-wide meta-analysis [18], weighted GRS was calculated for each participant in this  
128 study as  $GRS = \sum (x_i * b_i)$ ; where  $x_i$  are individual's genotype (0, 1, 2) for SNP  $i$ , and  $b_i$  are the  
129 effect size of this SNP. Linkage disequilibrium (LD) pruning was performed in advance to eliminate  
130 possible LD that existed between SNPs. None of the 14 SNPs were removed after pruning. To  
131 illustrate the different cumulative incidence of fracture in participants with different genetic profiles,  
132 we divided the participants into three GRS groups based on their weighted GRS, using distributions  
133 of 25%, 50%, and 25%.

## 134 2.6. Fracture probability

135 Since BMD measurement was unavailable for over 90% of the participants in this study sample,  
136 the existing FRAX score calculated by the FRAX without BMD (US FRAX version 3.0) for the 10-year  
137 probability of MOF and hip fracture in the data was used. The performance of FRAX with BMD

138 according to race and GRS will be addressed in a different study. All predicted fracture probability  
139 in this study was estimated by FRAX without BMD, unless noted differently. The observed 10-year  
140 cumulative fracture incidence was assessed by race and GRS groups. The cumulative incidence  
141 function (CIF) was applied to derive the observed 10-year fracture probability for MOF, and hip  
142 fracture accounting for competing mortality risk [33].

### 143 *2.7. Statistical Analysis*

144 Demographic and baseline clinical characteristics are presented as mean  $\pm$  SD for continuous  
145 variables or frequencies (%) for categorical variables. Differences between the two groups were  
146 examined by using Student's t-test for continuous variables and by using chi-square tests for  
147 categorical variables, respectively. The ratio between FRAX predicted fracture probability and  
148 observed fracture probability (POR), with the corresponding 95% CI, was calculated for each group.  
149 Multivariable Cox proportional hazard models were employed to assess the effect GRS and race had  
150 on survival time to the first fracture or death with adjusting for baseline FRAX probability.

151 A sensitivity analysis was conducted on a small sample (N=14,722) in which participants who  
152 received interventions in any of the three clinical trials, namely Calcium and Vitamin D Trial (CAD),  
153 Hormone Therapy Trial (HT), and Dietary Modification Trial (DM) were excluded. Statistical  
154 analyses were performed using the SAS 9.4 (SAS Institute, Inc., Cary, NC, USA).

## 156 **3. Results**

157 This section may be divided by subheadings. It should provide a concise and precise description  
158 of the experimental results, their interpretation as well as the experimental conclusions that can be  
159 drawn.

### 160 *3.1. Baseline characteristics*

161 The study included a total of 23,981 women for analysis. During an average of 12 years of  
162 follow-up, 5,555 (23.23%) women died, and 1,637 (6.9%) women sustained at least one MOF during  
163 the follow-up. **Table 1.** compares the baseline characteristics of women with MOF and women  
164 without an MOF during the follow-up. Weighted GRS was significantly higher in women who  
165 sustained an MOF than in those who did not ( $p < .0001$ ). Women who sustained an MOF were also  
166 older, had lower body mass index (BMI), more alcohol consumption, a higher prevalence of prior  
167 fractures, and more hip fractures in their family history. FRAX scores of both MOF and hip were  
168 significantly higher in women with a fracture incidence ( $p < .0001$ ). The mean of GRS between races  
169 are significantly different (Supplemental Figure 1).

170

171  
172

**Table 1.** Baseline Characteristics of 23,981 women according to whether they sustained a MOF during follow-up

	Subjects with major osteoporotic fracture event (n =1637)	Subjects without major osteoporotic fracture event (n =22,281 )	p-value
<b>Age (year), Mean ± SD</b>	67.99 ± 6.52	63.26 (±7.32)	<b>&lt;0.0001</b>
<b>Weight (kg), Mean ± SD</b>	73.59 ± 15.21	77.32 (±16.92)	<b>&lt;0.0001</b>
<b>Height (cm), Mean ± SD</b>	161.25 ± 6.30	161.06 (±6.29)	0.28
<b>Body mass index (kg/m<sup>2</sup>), Mean ± SD</b>	28.27 ± 6.30	29.73 (±6.09)	<b>&lt;0.0001</b>
<b>Smoking, n (%)</b>			
Never	858 (52.42)	11,704 (52.52)	
Past	639 (39.03)	8,448 (37.92)	0.35
Current	140 (8.55)	2,129 (9.56)	
<b>≥3 alcoholic drinks per day, n (%)</b>			
Yes	24 (1.47)	216 (0.97)	
No	1,613 (98.53)	22,065 (99.03)	0.05
<b>Rheumatoid arthritis, n (%)</b>			
Yes	109 (6.66)	1,500 (6.73)	
No	1,528 (93.34)	20,781 (93.27)	0.91
<b>Previous fragility fractures, n (%)</b>			
Yes	835 (51.01)	6,902 (30.98)	
No	802 (48.99)	15,379 (95.04)	<b>&lt;0.0001</b>
<b>Familial history of hip fracture, n (%)</b>			
Yes	271 (16.55)	2,156 (9.68)	
No	1,366 (83.45)	20,125 (93.64)	<b>&lt;0.0001</b>
<b>Race, n(%)</b>			
Caucasian	1255 (76.66)	7948 (35.67)	
American Indian	24 (1.47)	535 (2.40)	
Asian	10 (0.61)	467 (2.10)	
African American	189 (11.55)	9231 (41.43)	
Hispanic	159 (9.71)	4100 (18.40)	<b>&lt;0.0001</b>
<b>GRS, Mean ± SD</b>	0.58 ± 0.12	0.56 ± 0.13	<b>&lt;0.0001</b>
<b>FRAX® for MOF (%), Mean ± SD</b>	13.51 ± 8.57	7.39 ± 6.27	<b>&lt;0.0001</b>
<b>FRAX® for hip fracture (%), Mean ± SD</b>	4.02 ± 5.45	1.61 ± 2.88	<b>&lt;0.0001</b>


173 GRS: genetic risk score calculated based on 14 fracture-related SNPs. Significant results are in boldface.

174 3.2. Performance of FRAX in predicting MOF and hip fracture


175 The crude 10-year cumulative incidence of MOF and hip fracture by the GRS group is shown  
 176 in **Figure 1**. Significant between-group differences were observed for both MOF ( p<.001) and hip  
 177 fracture (p<.001). The incidences of MOF and hip fracture were greater in the high GRS group. The  
 178 crude 10-year cumulative incidence of MOF and hip fracture by race is shown in **Figure 2**.

179 Significant between-group differences were observed for both MOF ( $p < .001$ ) and hip fracture  
180 ( $p < .001$ ). The incidence of MOF and hip fracture were higher in Caucasian women.

181  
182 **Figure 1.** Crude (unadjusted) 10-year cumulative incidence of major osteoporotic (A) and hip fracture (B)  
183 stratified by the GRS group, including competing mortality risk. The difference in the cumulative incidence  
184 rates among different GRS groups was tested by using Gray's test,  $p$ -value  $< 0.01$  indicating a significant  
185 difference between the groups.  
186



187 **Figure 2.** Crude (unadjusted) 10-year cumulative incidence of major osteoporotic (A) and hip fracture (B)  
188 stratified by race, including competing mortality risk. The difference in the cumulative incidence rates  
189 among different racial groups was tested by using Gray's test,  $p$ -value  $< 0.01$  indicating a significant  
190 difference between the groups.




191 The predicted versus observed 10-year probability of MOF by GRS groups, with accounting  
192 for competing mortality, are shown in **Figure 3A**. The 10-year MOF probability derived from  
193 FRAX significantly overestimated risk across all GRS groups. The greatest overestimation by  
194 FRAX was observed in women who had low GRS, in which the 10-year predicted probability of  
195 MOF was 6.02% versus observed 3.74%, with a corresponding predicted/observed ratio (POR)  
196 of 1.61 (95% CI, 1.45-1.79), followed by the high GRS group with a POR of 1.38 (95% CI, 1.27-  
197 1.50); and in the median GRS group, the POR was 1.40 (95% CI, 1.32-1.49). For hip fracture  
198 outcome, where the 10-year predicted probability calculated by FRAX overestimated fracture  
199 risk in all GRS groups, however, with similar POR across the three GRS groups (**Figure 3B**).

200

201

202  
203  
204

**Figure 3.** Observed versus predicted 10-year major osteoporotic fracture (A) and hip fracture (B) probability stratified by the GRS group. The dotted line indicates a relative ratio of 1 (reference line), ratio >1 indicates that FRAX overestimates fracture probability.




205

206 The predicted versus observed 10-year probability of MOF by racial groups, with  
207 competing mortality risk accounted for are shown in **Figure 4A**. The 10-year probability of MOF  
208 calculated by FRAX significantly overestimated fracture risk in most racial groups, and the  
209 greatest overestimation was observed in Asian women. In Asian women, the predicted 10-year  
210 probability of MOF was 7.26% versus observed 2.03%, and the POR was 3.5 (95% CI 2.48-4.81).  
211 In African American women, the predicted 10-year probability of MOF was 3.79% as opposed  
212 to observed 1.46%, with the POR being 2.59 (95% CI 2.33-2.87). The 10-year probability of hip  
213 fracture estimated without BMD overestimated risk in all racial groups except American  
214 Indians. The 10-year predicted probability of hip fracture was in this group was 1.75% as  
215 opposed to observed 1.91%, with the POR being 0.91 (95% CI 0.46-1.62) (**Figure 4B**).

216  
217  
218

**Figure 4.** Observed versus predicted 10-year major osteoporotic fracture (A) and hip fracture (B) probability stratified by race. The dotted line indicates a relative ratio of 1 (reference line), ratio >1 indicates that FRAX overestimates fracture probability.



219

220

221

222 3.3. Race/ethnicity and the fracture outcome

223 In the multivariate Cox proportional hazard model, after adjusting for baseline FRAX  
224 probability in the model, weighted GRS calculated from 14 fracture-related SNPs was  
225 significantly associated with subsequent MOF. Compared to the low GRS group, the 10-year  
226 probability of MOF was 21% higher for women with medium genetic risk (HR=1.21, 95% CI 1.05-  
227 1.39) and 30% higher for women with high genetic risk (HR=1.30, 95% CI 1.12-1.50). Similar  
228 findings with hip fracture outcomes were observed. Compared to the low GRS group, the 10-  
229 year probability of hip fracture was 27% higher for women in the medium GRS group (HR=1.27,  
230 95% CI 1.04-1.55) and 46% higher for women in the high GRS group (HR=1.46, 95% CI 1.17-1.80)  
231 (Table 2).

232 **Table 2.** Hazard Ratios (HR) with 95% confidence interval (CI) for outcomes of incidence fracture  
233 according to the GRS group, adjusted for FRAX score: Results of multivariate Cox proportional hazard  
234 model.

	Major osteoporotic fracture HR (95 % CI)	Hip fracture HR (95 % CI)
<b>Adjusted for FRAX probability</b>		
low	1(reference)	1(reference)
medium	<b>1.21 (1.05 -1.39)</b>	<b>1.27 (1.04 -1.55)</b>
high	<b>1.30 (1.12 -1.50)</b>	<b>1.46 (1.17 -1.80)</b>
<b>Adjusted for FRAX probability + race</b>		
low	1(reference)	1(reference)
medium	1.01 (0.88 -1.16)	1.00 (0.81 -1.22)
high	1.08 (0.92 -1.25)	1.17 (0.93 -1.46)

235 *Significant results are in boldface.*

236 After controlling for baseline fracture probability estimated by FRAX, race remained a  
237 significant predictor of subsequent MOF and hip fracture. Compared to Caucasian women,  
238 Asian women had a 78% lower hazard of MOF (HR=0.22, 95% CI 0.12-0.41) and hip fracture  
239 (HR=0.22, 95% CI 0.09-0.52). Similarly, the FRAX-adjusted hazard ratio of MOF and hip fracture  
240 for African-American women and Hispanic women were also significantly lower (Table 3).

241 **Table 3.** Hazard Ratios (HR) with 95% confidence interval (CI) for outcomes of incidence fracture  
242 according to race, adjusted for FRAX score: Results of multivariate Cox proportional hazard model.

	Major osteoporotic fracture HR (95 % CI)	Hip fracture HR (95 % CI)
<b>Adjusted for FRAX probability</b>		
Caucasian	1(reference)	1(reference)
American Indian	<b>0.40 (0.26 -0.59)</b>	<b>0.39 (0.21 -0.70)</b>
Asian	<b>0.22 (0.12 -0.41)</b>	<b>0.22 (0.09 -0.52)</b>
AA	<b>0.24 (0.20 -0.28)</b>	<b>0.22 (0.17 -0.27)</b>
Hispanic	<b>0.44 (0.37 -0.52)</b>	<b>0.25 (0.20 -0.34)</b>
<b>Adjusted for FRAX probability + GRS group</b>		
Caucasian	1(reference)	1(reference)
American Indian	<b>0.39 (0.26 -0.59)</b>	<b>0.38 (0.21 -0.68)</b>
Asian	<b>0.22 (0.12 -0.40)</b>	<b>0.20 (0.09 -0.49)</b>
AA	<b>0.24 (0.20 -0.29)</b>	<b>0.20 (0.18 -0.28)</b>
Hispanic	<b>0.43 (0.36 -0.52)</b>	<b>0.24 (0.18 -0.32)</b>

243 *Significant results are in boldface.*

244

### 245 3.4. GRS and the fracture outcome

246 The potential impact of GRS on the estimated probabilities of MOF and hip fractures across  
247 different racial groups was also assessed. When adjusted for FRAX probability and race, high GRS  
248 was associated with an increased probability of MOF (GRS high vs. low: HR=1.08, 95% CI 0.92-1.25)  
249 and of hip fracture (HR=1.17, 95% CI 0.93-1.46) (**Table 2**); however, the increase was not statistically  
250 significant in both outcomes. When adjusted for the baseline FRAX probability and GRS  
251 simultaneously, the impact of race on the estimated probabilities MOF and hip fracture was slightly  
252 attenuated but remained statistically significant. Compared to Caucasian women, American  
253 Indians, Asians, African American, and Hispanic women had a 61%, 78%, 76%, and 57% lower  
254 hazard of MOF, respectively. Similar findings were observed with hip fracture outcomes (**Table 3**).

### 255 3.5. Sensitivity analysis

256 We conducted a sensitivity analysis in which we excluded subjects who received intervention  
257 in either of the three clinical trials. When adjusted for the FRAX probability, we observed an  
258 increased HR of MOF with GRS (GRS high as opposed to low: HR=1.39, 95% CI 1.10 – 1.74);  
259 whereas the impact of GRS on the estimated probability of hip fracture attenuated slightly  
260 (HR=1.41, 95% CI 1.03-1.95), but remained significant. However, when adjusted for both race and  
261 FRAX probability, the association between GRS and hip fracture was not significant  
262 (Supplementary Table 1). When controlling for GRS and FRAC probability, the effects of race on the  
263 estimated probabilities of MOF and hip fracture remained significant. Compare to Caucasian  
264 women, the race and FRAX-adjusted hazard of MOF was 90%, 78%, and 66% lower in Asian,  
265 African-American, and Hispanic women, respectively (**Supplementary Table 2**).

## 266 4. Discussion

267 The present study found that FRAX overestimated the risk of fracture in women aged 50-79  
268 years, and the degree of overestimation by FRAX in the low GRS group is greater than high genetic  
269 risk groups in both outcomes of MOF and hip fracture. In the multivariate analysis, genetic  
270 profiling was further demonstrated to be a significant predictor of MOF and hip fracture,  
271 independent of FRAX probability.

272 Genetic factors that influence osteoporotic fracture risk have been long recognized. Genetics  
273 are determinants of bone structure and thus a predisposition to fragility. Hereditary factors  
274 contribute almost half of the variance in fracture susceptibility [25]. However, genetic factors are  
275 not counted in the FRAX or any other existing clinical fracture risk assessment models. Since FRAX  
276 is the most commonly used fracture prediction model, determining if the performance of FRAX  
277 varies with different genetic profiling has become crucially important. The largest and most  
278 updated GWAS meta-analysis has identified 14 SNPs that are significantly associated with fracture  
279 risk at a genome-wide significant level [25]. Although these individual SNPs have modest effect  
280 size on fracture risk, the GRS, as summarized from these individual risk SNPs, enables us to  
281 examine if FRAX performance varies with different genetic risk factors. The varied prediction  
282 performance of FRAX by GRS observed in our study suggests that the accuracy of FRAX can be  
283 improved by incorporating genetic profiling. Several studies suggested that genetic profiling may  
284 help improve the accuracy of various fracture prediction models. For example, GRS of 39 SNPs  
285 increased the precision of nonvertebral fracture prediction in postmenopausal Korean women [34].  
286 Additionally, a profiling of 63 SNPs improved the accuracy of non-trauma fracture prediction [29].  
287 One of our recent studies on the US older men also found that GRS is one of the most important  
288 variables in MOF prediction models developed by the gradient boosting approach (manuscript  
289 under review).

290 The present study also provides compelling evidence that FRAX overestimates the risk of MOF  
291 and hip fracture in women 50-79 years old, across all racial groups, but especially in minorities. In  
292 Asian, African-American, and Hispanic women, the observed probability of fracture, in terms of  
293 both MOF and hip fracture, was significantly lower than the risk estimated by FRAX, indicating  
294 that the FRAX did not adequately capture racial and ethnic differences of fracture risk.  
295 Additionally, our multivariate analysis demonstrated that race is a significant predictor of MOF  
296 and hip fracture independent of the cumulative fracture risk estimated by FRAX, suggesting that  
297 FRAX does not have adequate adjustment for racial difference. Racial and ethnic difference that  
298 influences fracture risk not being adjusted for adequately in the FRAX has long been a concern [13].  
299 As we know, the US FRAX was calibrated from the REP data, composed predominantly of  
300 Caucasians. For non-Caucasian minorities, the FRAX estimates were adjusted based on race-specific  
301 hip fracture incidence rates and race-specific mortality [46]. This adjustment for minorities in FRAX  
302 is not empirically based, thus making the prediction accuracy of FRAX increasingly uncertain,  
303 especially for MOF, a composite of hip, humerus, forearm, and clinical vertebral fractures. The  
304 current FRAX adjustment model, based on race-specific hip fracture incidence rate and race-specific  
305 mortality, remains likely to be inadequate for MOF risk estimation in minorities. In this study, we  
306 observed that the overestimated risk for MOF by FRAX was much higher than that for hip fracture,  
307 at least validated that the US FRAX has not adjusted race adequately for MOF. A prior study  
308 conducted on the same WHI sample assessing the accuracy of FRAX without BMD in predicting  
309 fracture also demonstrated that the FRAX has significant lower sensitivity in identifying incidence  
310 fractures in African-American and Hispanic women [35]. Another study on 2266 postmenopausal  
311 women who participated in the Hong Kong Osteoporosis study revealed that the predictive  
312 accuracy of FRAX with BMD was not substantially different from the model with BMD alone [36].  
313 Considering the generally lower incidence of fracture in Asians than in Caucasians and the  
314 prominent effect of BMD in fracture prediction in the Asian population, the absence of BMD in the  
315 present study may explain the significant overestimation of fracture in this racial group. Besides,  
316 inconsistent findings regarding the performance of FRAX without BMD was reported in several  
317 other studies. Leslie et al. observed that the fracture probability estimated without BMD  
318 overestimate risk among the general population [37], which are consistent with findings from the  
319 present study. Other studies have reported underestimation of fracture risk by FRAX [15, 38, 39],  
320 but their methodologies were found to be problematic lately because they either comparing  
321 incidence with probabilities or failed to take the competing mortality risk into account [40].

322 When both FRAX probability and race were adjusted simultaneously in the multivariate  
323 model, the effect of GRS was reduced, which be due to the following reasons. First, genetic profiling  
324 regarding osteoporosis or osteoporotic fracture varies in different racial groups; the effect of race  
325 and GRS on fracture could be overlapping (See Supplemental Figure 1). Second, the genetic effect  
326 on fracture probability may not be fully captured by the limited number of discovered risk SNPs.  
327 With more fracture-related genetic components being discovered in the future, a larger effect of  
328 GRS on fracture risk prediction should be foreseen.

329 Limitations to this study are acknowledged. First, the WHI data we used only included  
330 women 50-79 years, so our findings may not apply to men or to women who are not in the study  
331 age range. Second, rare genetic variants with high effect size were not included in the present  
332 study, because risk SNPs used in this analysis were identified from a GWAS meta-analysis study,  
333 which likely discovered common variants, not rare variants [18]. The limited number of fracture-  
334 associated SNPs may not capture all genetic risk, which partially explained the reduced effect of  
335 GRS in the model when both FRAX probability and race were included. Third, our study only  
336 focuses on FRAX without BMD because the BMD measurement was unavailable for most of the  
337 study subjects. The performance of FRAX with BMD will be examined in a future study. Finally, the  
338 sample size of Asian and American Indian subjects were very small in this study; the results may,  
339 therefore, be underpowered.

## 340 5. Conclusions

341 To the best of our knowledge, this is the first study to assess FRAX performance in the  
342 prediction of MOF and hip fractures in groups with different genetic profiling and of various races.  
343 Our findings suggested genetic profiling of an individual should be considered in fracture  
344 prediction, as genetic factors have been demonstrated to be a significant risk factor for osteoporotic  
345 fracture, independent of FRAX. Our results also demonstrated that FRAX performed differently in  
346 different races, and thus the effect of race in osteoporotic fracture prediction has not heretofore  
347 adequately been taken accounted for by existing FRAX models. Fully integrating genetic profiling  
348 and racial factors into the existing fracture assessment model is very likely to improve the accuracy  
349 of fracture prediction. Thus, developing racial/ethnic-specific, individualized fracture risk  
350 assessment models will provide more accurate fracture risk assessment. Further studies, especially  
351 these including men, larger sample of minorities, and more comprehensive fracture-associated  
352 genetic variants, are warranted.

353

354 **Supplementary Materials:** The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Figure S1: Box plot for  
355 the distribution of GRS in different race groups (N=23,981), Table S1: Hazard Ratios (HR) with 95% confidence  
356 interval (CI) for outcomes of Incidence fracture according to GRS group, adjusted for FRAX score: results from  
357 sensitivity analysis after excluding subjects who received intervention in either of the three clinical trials.  
358 (N=14,722), Table S2: Hazard Ratios (HR) with 95% confidence interval (CI) for outcomes of incidence fracture  
359 according to race, adjusted for FRAX score: results from sensitivity analysis after excluding subjects who  
360 received intervention in either of the three clinical trials. (N=14,722)

361 **Author Contributions:** conceptualization, Q.W.; methodology, Q.W., X.X. and Y.X.; software, Y.X.; validation,  
362 Q.W., X.X. and Y.X.; formal analysis, Y.X.; investigation, Q.W., X.X. and Y.X.; resources, Q.W.; data curation, X.X.  
363 and Y.X.; writing—original draft preparation, Q.W., X.X.; writing—review and editing, Q.W. X.X. and Y.X.;  
364 visualization, X.X. and Y.X.; supervision, Q.W.; project administration, Q.W.; funding acquisition, Q.W.

365 **Funding:** This research was funded by a grant from the National Institute of General Medical Sciences (GR08954), a  
366 grant from the National Institute on Minority Health and Health Disparities of the National Institutes of Health  
367 (R15MD010475).

368 **Acknowledgments:** The data/analyses presented in the current publication are based on the use of study data  
369 downloaded from the dbGaP web site, under phs000200 ([https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study\\_id=phs000200.v12.p3](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3)). The research and analysis described in the current publication were  
370 supported by the Genome Acquisition to Analytics (GAA) Research Core of the Personalized Medicine Center of  
371 Biomedical Research Excellence in the Nevada Institute of Personalized Medicine, and the National Supercomputing  
372 Institute at the University of Nevada Las Vegas provided facilities for bioinformatical analysis in this study.  
373

374 **Conflicts of Interest:** The authors declare no conflict of interest.

375

## 376 References

- 377 1. 1. Johnell, O. & Kanis, J. A. (2004) An estimate of the worldwide prevalence, mortality and disability  
378 associated with hip fracture, *Osteoporosis international : a journal established as result of cooperation  
379 between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.*  
380 15, 897-902.
- 381 2. 2. Johnell, O. & Kanis, J. A. (2006) An estimate of the worldwide prevalence and disability associated with  
382 osteoporotic fractures, *Osteoporosis international : a journal established as result of cooperation between  
383 the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.* 17, 1726-  
384 33.
- 385 3. 3. Sözen, T., Özışık, L. & Başaran, N. Ç. (2017) An overview and management of osteoporosis, *Eur J*  
386 *Rheumatol.* 4, 46-56.
- 387 4. 4. Reginster, J. Y. & Burlet, N. (2006) Osteoporosis: a still increasing prevalence, *Bone.* 38, S4-9.
- 388 5. 5. Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper,  
389 M., Luckey, M. M., McClung, M. R., Pollack, R. P. & Petak, S. M. (2010) American Association of Clinical  
390 Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of

- 391 postmenopausal osteoporosis, *Endocrine practice : official journal of the American College of*  
392 *Endocrinology and the American Association of Clinical Endocrinologists.* 16 Suppl 3, 1-37.
- 393 6. Wright, N. C., Looker, A. C., Saag, K. G., Curtis, J. R., Delzell, E. S., Randall, S. & Dawson-Hughes, B.  
394 (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral  
395 density at the femoral neck or lumbar spine, *Journal of bone and mineral research : the official journal of*  
396 *the American Society for Bone and Mineral Research.* 29, 2520-2526.
- 397 7. Dyer, S. M., Crotty, M., Fairhall, N., Magaziner, J., Beaupre, L. A., Cameron, I. D., Sherrington, C. &  
398 *Fragility Fracture Network Rehabilitation Research Special Interest, G.* (2016) A critical review of the long-  
399 term disability outcomes following hip fracture, *BMC Geriatr.* 16, 158-158.
- 400 8. Sánchez-Riera, L., Carnahan, E., Vos, T., Veerman, L., Norman, R., Lim, S. S., Hoy, D., Smith, E., Wilson,  
401 N., Nolla, J. M., Chen, J. S., Macara, M., Kamalaraj, N., Li, Y., Kok, C., Santos-Hernández, C. & March, L.  
402 (2014) The global burden attributable to low bone mineral density, *Annals of the Rheumatic Diseases.* 73,  
403 1635.
- 404 9. Harvey, N., Dennison, E. & Cooper, C. (2010) Osteoporosis: impact on health and economics, *Nature*  
405 *Reviews Rheumatology.* 6, 99-105.
- 406 10. Gnudi, S. & Malavolta, N. (2003) Comparison Between T-Score-Based Diagnosis of Osteoporosis and  
407 Specific Skeletal Site Measurements: Prognostic Value for Predicting Fracture Risk, *Journal of Clinical*  
408 *Densitometry.* 6, 267-273.
- 409 11. Schuit, S. C., van der Klift, M., Weel, A. E., de Laet, C. E., Burger, H., Seeman, E., Hofman, A.,  
410 Uitterlinden, A. G., van Leeuwen, J. P. & Pols, H. A. (2004) Fracture incidence and association with bone  
411 mineral density in elderly men and women: the Rotterdam Study, *Bone.* 34, 195-202.
- 412 12. Siris, E. S., Chen, Y. T., Abbott, T. A., Barrett-Connor, E., Miller, P. D., Wehren, L. E. & Berger, M. L.  
413 (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures, *Arch Intern*  
414 *Med.* 164, 1108-12.
- 415 13. Kanis, J. A. (2008) Assessment of osteoporosis at the primary health-care level. Technical Report,  
416 <http://www.shefacuk/FRAX>.
- 417 14. Kanis, J. A., Oden, A., Johnell, O., Johansson, H., De Laet, C., Brown, J., Burckhardt, P., Cooper, C.,  
418 Christiansen, C., Cummings, S., Eisman, J. A., Fujiwara, S., Gluer, C., Goltzman, D., Hans, D., Krieg, M. A.,  
419 La Croix, A., McCloskey, E., Mellstrom, D., Melton, L. J., 3rd, Pols, H., Reeve, J., Sanders, K., Schott, A. M.,  
420 Silman, A., Torgerson, D., van Staa, T., Watts, N. B. & Yoshimura, N. (2007) The use of clinical risk factors  
421 enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women,  
422 *Osteoporosis international : a journal established as result of cooperation between the European*  
423 *Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.* 18, 1033-46.
- 424 15. Sornay-Rendu, E., Munoz, F., Delmas, P. D. & Chapurlat, R. D. (2010) The FRAX tool in French women:  
425 How well does it describe the real incidence of fracture in the OFELY cohort?, *Journal of bone and mineral*  
426 *research : the official journal of the American Society for Bone and Mineral Research.* 25, 2101-7.
- 427 16. Crandall, C. J., Schousboe, J. T., Morin, S. N., Lix, L. M. & Leslie, W. (2019) Performance of FRAX and  
428 FRAX-Based Treatment Thresholds in Women Aged 40 Years and Older: The Manitoba BMD Registry,  
429 *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral*  
430 *Research.* 34, 1419-1427.
- 431 17. Briot, K., Paternotte, S., Kolta, S., Eastell, R., Felsenberg, D., Reid, D. M., Glüer, C.-C. & Roux, C. (2014)  
432 FRAX®: Prediction of Major Osteoporotic Fractures in Women from the General Population: The OPUS  
433 Study, *PLOS ONE.* 8, e83436.
- 434 18. Estrada, K., Stykarsdottir, U., Evangelou, E., Hsu, Y. H., Duncan, E. L., Ntzani, E. E., Oei, L., Albagha, O.,  
435 M. Amin, N., Kemp, J. P., Koller, D. L., Li, G., Liu, C. T., Minster, R. L., Moayyeri, A., Vandenput, L., Willner, D., Xiao,  
436 S. M., Yerges-Armstrong, L. M., Zheng, H. F., Alonso, N., Eriksson, J., Kammerer, C. M., Kaptoge, S. K., Leo, P.,  
437 J. Thorleifsson, G. Wilson, S. G. Wilson, J. F. Aalto, V. Alen, M. Aragaki, A. K. Aspelund, T. Center, J.  
438 R. Dailiana, Z. Duggan, D. J. Garcia, M. Garcia-Giralt, N. Giroux, S. Hallmans, G. Hocking, L. J. Husted, L.  
439 B. Jameson, K. A. Khusainova, R. Kim, G. S. Kooperberg, C. Koromila, T. Kruk, M. Laaksonen, M. Lacroix, A.  
440 Z. Lee, S. H. Leung, P. C. Lewis, J. R. Masi, L. Mencej-Bedrac, S. Nguyen, T. V. Nogue, X. Patel, M. S. Prezelj,  
441 J. Rose, L. M. Scollen, S. Siggeirsdottir, K. Smith, A. V. Svensson, O. Trompet, S. Trummer, O. van Schoor, N.  
442 M. Woo, J. Zhu, K. Balcells, S. Brandi, M. L. Buckley, B. M. Cheng, S. Christiansen, C. Cooper, C. Dedoussis,  
443 G. Ford, I. Frost, M. Goltzman, D. Gonzalez-Macias, J. Kahonen, M. Karlsson, M. Khusnutdinova, E. Koh, J.  
444 M. Kollia, P. Langdahl, B. L. Leslie, W. D. Lips, P. Ljunggren, O. Lorenc, R. S. Marc, J. Mellstrom, D. Obermayer-  
445 Pietsch, B. Olmos, J. M. Pettersson-Kymmer, U. Reid, D. M. Riancho, J. A. Ridker, P. M. Rousseau, F. Slagboom,  
446 P. E. Tang, N. L., et al. (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals  
447 14 loci associated with risk of fracture, *Nature genetics.* 44, 491-501.

- 448 19. Melton, L. J., 3rd (1996) History of the Rochester Epidemiology Project, Mayo Clinic proceedings. 71,  
449 266-74.
- 450 20. Dawson-Hughes, B., Tosteson, A. N., Melton, L. J., 3rd, Baim, S., Favus, M. J., Khosla, S. & Lindsay, R.  
451 L. (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA,  
452 Osteoporosis Int. 19, 449-58.
- 453 21. (2007) WHO scientific group on the assessment of osteoporosis at the primary health-care Level in  
454 Summary Meeting Report, Brussels, Belgium, 5-7 May 2004 (the World Health Organization Collaborating  
455 Centre for Metabolic Bone Diseases, ed)
- 456 22. Stewart, T. L. & Ralston, S. H. (2000) Role of genetic factors in the pathogenesis of osteoporosis, The  
457 Journal of endocrinology. 166, 235-45.
- 458 23. Mikkola, T. M., Sipilä, S., Rantanen, T., Sievänen, H., Suominen, H., Kaprio, J., Koskenvuo, M.,  
459 Kauppinen, M. & Heinonen, A. (2008) Genetic and Environmental Influence on Structural Strength of  
460 Weight-Bearing and Non-Weight-Bearing Bone: A Twin Study, Journal of Bone and Mineral Research. 23,  
461 492-498.
- 462 24. Koromani, F., Trajanoska, K., Rivadeneira, F. & Oei, L. (2019) Recent Advances in the Genetics of  
463 Fractures in Osteoporosis, Front Endocrinol (Lausanne). 10, 337-337.
- 464 25. Michaëlsson, K., Melhus, H., Ferm, H., Ahlbom, A. & Pedersen, N. L. (2005) Genetic Liability to  
465 Fractures in the Elderly, Archives of Internal Medicine. 165, 1825-1830.
- 466 26. Kim, S. K. (2018) Identification of 613 new loci associated with heel bone mineral density and a  
467 polygenic risk score for bone mineral density, osteoporosis and fracture, PLOS ONE. 13, e0200785.
- 468 27. Morris, J. A., Kemp, J. P., Youlten, S. E., Laurent, L., Logan, J. G., Chai, R. C., Vulpescu, N. A., Forgetta,  
469 V., Kleinman, A., Mohanty, S. T., Sergio, C. M., Quinn, J., Nguyen-Yamamoto, L., Luco, A.-L., Vijay, J.,  
470 Simon, M.-M., Pramatarova, A., Medina-Gomez, C., Trajanoska, K., Ghirardello, E. J., Butterfield, N. C.,  
471 Curry, K. F., Leitch, V. D., Sparkes, P. C., Adoum, A.-T., Mannan, N. S., Komla-Ebri, D. S. K., Pollard, A. S.,  
472 Dewhurst, H. F., Hassall, T. A. D., Beltejar, M.-J. G., Agee, M., Alipanahi, B., Auton, A., Bell, R. K., Bryc, K.,  
473 Elson, S. L., Fontanillas, P., Furlotte, N. A., McCreight, J. C., Huber, K. E., Litterman, N. K., McIntyre, M.  
474 H., Mountain, J. L., Noblin, E. S., Northover, C. A. M., Pitts, S. J., Sathirapongsasuti, J. F., Sazonova, O. V.,  
475 Shelton, J. F., Shringarpure, S., Tian, C., Tung, J. Y., Vacic, V., Wilson, C. H., Adams, D. J., Vaillancourt, S.  
476 M., Kaptoge, S., Baldock, P., Cooper, C., Reeve, J., Ntzani, E. E., Evangelou, E., Ohlsson, C., Karasik, D.,  
477 Rivadeneira, F., Kiel, D. P., Tobias, J. H., Gregson, C. L., Harvey, N. C., Grundberg, E., Goltzman, D.,  
478 Adams, D. J., Lelliott, C. J., Hinds, D. A., Ackert-Bicknell, C. L., Hsu, Y.-H., Maurano, M. T., Croucher, P. I.,  
479 Williams, G. R., Bassett, J. H. D., Evans, D. M., Richards, J. B. & andMe Research, T. (2019) An atlas of  
480 genetic influences on osteoporosis in humans and mice, Nature genetics. 51, 258-266.
- 481 28. Bush, W. S. & Moore, J. H. (2012) Chapter 11: Genome-wide association studies, PLoS Comput Biol. 8,  
482 e1002822-e1002822.
- 483 29. Ho-Le, T. P., Center, J. R., Eisman, J. A., Nguyen, H. T. & Nguyen, T. V. (2017) Prediction of Bone  
484 Mineral Density and Fragility Fracture by Genetic Profiling, Journal of bone and mineral research : the  
485 official journal of the American Society for Bone and Mineral Research. 32, 285-293.
- 486 30. Eriksson, J., Evans, D. S., Nielson, C. M., Shen, J., Srikanth, P., Hochberg, M., McWeeney, S., Cawthon,  
487 P. M., Wilmot, B., Zmuda, J., Tranah, G., Mirel, D. B., Challa, S., Mooney, M., Crenshaw, A., Karlsson, M.,  
488 Mellstrom, D., Vandenput, L., Orwoll, E. & Ohlsson, C. (2015) Limited clinical utility of a genetic risk score  
489 for the prediction of fracture risk in elderly subjects, Journal of bone and mineral research : the official  
490 journal of the American Society for Bone and Mineral Research. 30, 184-94.
- 491 31. Gibson, G. (2019) On the utilization of polygenic risk scores for therapeutic targeting, PLOS Genetics.  
492 15, e1008060.
- 493 32. (1998) Design of the Women's Health Initiative clinical trial and observational study. The Women's  
494 Health Initiative Study Group, Control Clin Trials. 19, 61-109.
- 495 33. Zhang, M.-J., Zhang, X. & Scheike, T. H. (2008) Modeling cumulative incidence function for competing  
496 risks data, Expert Rev Clin Pharmacol. 1, 391-400.
- 497 34. Lee, S. H., Lee, S. W., Ahn, S. H., Kim, T., Lim, K. H., Kim, B. J., Cho, E. H., Kim, S. W., Kim, T. H., Kim,  
498 G. S., Kim, S. Y., Koh, J. M. & Kang, C. (2013) Multiple gene polymorphisms can improve prediction of  
499 nonvertebral fracture in postmenopausal women, Journal of bone and mineral research : the official journal  
500 of the American Society for Bone and Mineral Research. 28, 2156-64.
- 501 35. Crandall, C. J., Larson, J., LaCroix, A., Cauley, J. A., LeBoff, M. S., Li, W., LeBlanc, E. S., Edwards, B. J.,  
502 Manson, J. E. & Ensrud, K. (2019) Predicting Fracture Risk in Younger Postmenopausal Women:  
503 Comparison of the Garvan and FRAX Risk Calculators in the Women's Health Initiative Study, Journal of  
504 general internal medicine. 34, 235-242.

- 505 36. Cheung, E., Cheung, C. L., Kung, A. W. & Tan, K. C. (2014) Possible FRAX-based intervention  
506 thresholds for a cohort of Chinese postmenopausal women, *Osteoporosis international : a journal*  
507 *established as result of cooperation between the European Foundation for Osteoporosis and the National*  
508 *Osteoporosis Foundation of the USA.* 25, 1017-23.
- 509 37. Leslie, W. D., Morin, S. N., Lix, L. M., Niraula, S., McCloskey, E. V., Johansson, H., Harvey, N. C. &  
510 Kanis, J. A. (2019) Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor  
511 Therapy: A Registry-Based Cohort Study, *Journal of bone and mineral research : the official journal of the*  
512 *American Society for Bone and Mineral Research.* 34, 1428-1435.
- 513 38. Bolland, M. J., Siu, A. T., Mason, B. H., Horne, A. M., Ames, R. W., Grey, A. B., Gamble, G. D. & Reid,  
514 I. R. (2011) Evaluation of the FRAX and Garvan fracture risk calculators in older women, *Journal of bone*  
515 *and mineral research : the official journal of the American Society for Bone and Mineral Research.* 26, 420-  
516 7.
- 517 39. Pluskiewicz, W., Adamczyk, P., Franek, E., Leszczynski, P., Sewerynek, E., Wichrowska, H.,  
518 Napiorkowska, L., Kostyk, T., Stuss, M., Stepien-Klos, W., Golba, K. S. & Drozdowska, B. (2010) Ten-year  
519 probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et  
520 al.—Conformity between methods and their clinical utility, *Bone.* 46, 1661-1667.
- 521 40. Kanis, J. A., Oden, A., Johansson, H. & McCloskey, E. (2012) Pitfalls in the external validation of FRAX,  
522 *Osteoporosis international : a journal established as result of cooperation between the European*  
523 *Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.* 23, 423-31.
- 524

525